Saxagliptin- Oral Medication Caution

8193

By: Pat Piper

The FDA wants to take another look at a pill approved in 2006 for control of glucose levels in people with type 2 diabetess. In a trial study published in the New England Journal of Medicine, saxagliptin (brand name Onglyza) was shown to coincide with an increased rate of hospitalization for heart failure of 27 percent compared to type 2s taking a placebo. The FDA has not asked prescribers and patients to stop taking saxagliptin, but to use caution while a review is underway.

Comments

comments

Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.